Buy
Average AnalystHold
Top AnalystNeutral
Stock Target AdvisorBuy
Average UserUSD 92.57
0.00 (0.00)%
USD 115.13B
0.02B
USD 90.03(-2.75%)
Symbol | Name | Exchange | GILD's Weight | Expense Ratio | Price(Change) | Market Cap |
---|---|---|---|---|---|---|
|
iShares Nasdaq US Biotech.. | XETRA | 10.20 % | 0.35 % | 0.00 (0.00%) | USD0.52B |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.